- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Eribulin Mesylate.
Displaying page 1 of 1.
EudraCT Number: 2013-004600-19 | Sponsor Protocol Number: PAINTER01 | Start Date*: 2014-01-21 |
Sponsor Name:Azienda Ospedaliera Fatebenefratelli e Oftalmico - Milano, Italy | ||
Full Title: Multicenter, interventional, single-arm, phase IV study evaluating tolerability of Eribulin and its relationship with a set of polymorphisms in an unselected population of female patients with meta... | ||
Medical condition: Patients with metastatic breast cancer | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001398-30 | Sponsor Protocol Number: MEDOPP437 | Start Date*: 2023-05-08 |
Sponsor Name:Medica Scientia Innovation Research, S.L. | ||
Full Title: PHASE II STUDY FOR PIK3CA/PTEN-ALTERED ADVANCED METAPLASTIC BREAST CANCER TREATED WITH MEN1611 MONOTHERAPY OR IN COMBINATION WITH ERIBULIN -THE SABINA STUDY- English PHASE II STUDY WITH MEN1611 M... | ||
Medical condition: Hormone Receptor (HR)-known/ Human Epidermial Growth Factor Receptor 2 (HER2)-negative, phosphatidylinositol-4,5-bisphosphate 3kinase catalytic subunit alpha (PIK3CA)/ Phosphatase and Tensin Homolo... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003019-21 | Sponsor Protocol Number: IMMU-132-05 | Start Date*: 2017-12-14 | ||||||||||||||||||||||||||
Sponsor Name:Immunomedics, Inc. | ||||||||||||||||||||||||||||
Full Title: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who R... | ||||||||||||||||||||||||||||
Medical condition: Relapsed/Refractory Triple-Negative Breast Cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) ES (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-005223-21 | Sponsor Protocol Number: D926PC00001 | Start Date*: 2022-06-16 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in Firs... | |||||||||||||
Medical condition: Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004201-33 | Sponsor Protocol Number: IMMU-132-09 | Start Date*: 2019-08-16 | |||||||||||||||||||||
Sponsor Name:Immunomedics, Inc. | |||||||||||||||||||||||
Full Title: Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Nega... | |||||||||||||||||||||||
Medical condition: Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) NL (Completed) ES (Ongoing) BE (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003543-11 | Sponsor Protocol Number: 16-214-02 | Start Date*: 2017-07-10 | |||||||||||
Sponsor Name:Nektar Therapeutics | |||||||||||||
Full Title: A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients with Select Locally Ad... | |||||||||||||
Medical condition: Locally Advanced or Metastatic Solid Tumor Malignancies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005620-12 | Sponsor Protocol Number: D9268C00001 | Start Date*: 2022-01-07 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator’s Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer... | |||||||||||||
Medical condition: Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) NL (Completed) BE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
